TY - JOUR T1 - Altered branched-chain α-keto acid metabolism is a feature of NAFLD in individuals with severe obesity JF - medRxiv DO - 10.1101/2022.02.07.22270618 SP - 2022.02.07.22270618 AU - Thomas Grenier-Larouche AU - Lydia Coulter Kwee AU - Yann Deleye AU - Paola Leon-Mimila AU - Jacquelyn M. Walejko AU - Robert W. McGarrah AU - Simon Marceau AU - Sylvain Trahan AU - Christine Racine AU - André C Carpentier AU - Aldons J. Lusis AU - Olga Ilkayeva AU - Marie-Claude Vohl AU - Adriana Huertas-Vazquez AU - André Tchernof AU - Svati H. Shah AU - Christopher B Newgard AU - Phillip J White Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/08/2022.02.07.22270618.abstract N2 - Hepatic de novo lipogenesis is influenced by the branched-chain α-keto acid dehydrogenase (BCKDH) kinase (BCKDK). We aimed to determine whether circulating levels of the immediate substrates of BCKDH, the branched-chain α-ketoacids (BCKAs) and hepatic BCKDK expression are associated with the presence and severity of non-alcoholic fatty liver disease (NAFLD).Eighty metabolites (3 BCKA, 14 amino acids, 43 acylcarnitines, 20 ceramides) were quantified in plasma from 288 bariatric surgery patients with severe obesity (BMI > 35 kg/m2) with scored liver biopsy samples. Metabolite principal component analysis (PCA) factors, BCKA, branched-chain amino acids (BCAA), and the BCKA:BCAA ratio were tested for associations with steatosis grade and presence of non-alcoholic steatohepatitis (NASH). Of all analytes tested, only the valine-derived BCKA, α-ketoisovalerate, and the BCKA:BCAA ratio were associated with both steatosis grade and NASH. Gene expression analysis in liver samples from two independent bariatric surgery cohorts showed that hepatic BCKDK mRNA expression correlates with steatosis, ballooning, and levels of the lipogenic transcription factor SREBP1. Experiments in AML12 hepatocytes showed that SREBP1 inhibition lowers BCKDK mRNA expression. These findings demonstrate that higher plasma levels of BCKA and hepatic expression of BCKDK are features of human NAFLD/NASH and identify SREBP1 as a transcriptional regulator of BCKDK.Competing Interest StatementPJW, TGL, and CBN have filed a patent application relating to the use of BCKA and the BCKA:BCAA ratio as a biomarker for NAFLD and NASH. CBN is a member of the Eli Lilly Global Diabetes Advisory Board. AT receives funding from Johnson & Johnson, Medtronic and GI Windows for studies on bariatric surgery, and acted as consultant for Bausch Health, Novo Nordisk and Biotwin.Funding StatementThe Authors acknowledge the invaluable collaboration of the surgery team, bariatric surgeons and biobank staff of the IUCPQ/QHLI and the participants of the studies. We thank Hugo Villamil and Samuel Canizales for sharing MOBES liver gene expression data. This work was supported by an American Diabetes Association Pathways to Stop Diabetes Initiator Award 1-16-INI-17 to PJW and Cardiovascular-Metabolic Fellowship 1-21-CMF-005 to JMW. NIH grants DK58398, DK121710, and DK124723 to CBN, NIH grant HL127009 to SHS, American Heart Association grant 17SFRN33670990 to SHS, a sponsored research agreement from Pfizer to CBN, and a Michael Smith Foreign Study Scholarship from the Canadian Institute of Health Research to TGL. MCV is Tier 1 Canada Research Chair in Genomics Applied to Nutrition and Metabolic Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Bio specimens were obtained from the Biobank of the Institut universitaire de cardiologie et de pneumologie de Quebec according to institutionally-approved management modalities. All studies were conducted according to the principles outlined in the Declaration of Helsinki and approved by the Institutional Review Boards at Universite Laval, UCLA, INMEGEN, and Duke University. All participants provided written, informed consentI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -